Vol 25/No. 3

The University of Hawaii Cancer Center hopes to address treatment needs through its planned Early Phase Clinical Research Center.

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.

The combination of the first-in-class inhibitor enasidenib plus venetoclax has generated excitement targeting IDH2 mutations in relapsed/refractory AML.

Sagar Lonial, MD, FACP, details how CAR T-cell therapies and off-the-shelf treatments are improving outcomes for patients with multiple myeloma.

Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer.

Maurie Markman, MD, discusses the need for a decision support strategy to assist oncologists in treatment selection for patients with actionable mutations.